Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Auditor change
89bio, Inc. (ETNB) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/15/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/09/2023 8-K Quarterly results
Docs: "89bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update"
06/09/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders...
Docs: "Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation of 89bio, Inc",
"Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation of 89bio, Inc"
05/04/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"89bio Reports First Quarter 2023 Financial Results and Provides Corporate Update"
03/27/2023 8-K Quarterly results
03/22/2023 8-K Quarterly results
03/10/2023 8-K Quarterly results
Docs: "89bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update"
01/06/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Loan and Security Agreement, among 89bio, Inc., 89bio Management, Inc., 89Bio Ltd., K2 HealthVentures LLC and Ankura Trust Company, LLC",
"Loan and Security Agreement, among 89bio, Inc., 89bio Management, Inc., 89Bio Ltd., K2 HealthVentures LLC and Ankura Trust Company, LLC"
11/10/2022 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"89bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update"
08/11/2022 8-K Quarterly results
06/30/2022 8-K Quarterly results
06/28/2022 8-K Quarterly results
06/07/2022 8-K Quarterly results
05/11/2022 8-K Quarterly results
03/24/2022 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"89bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update"
02/24/2022 8-K Quarterly results
01/24/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Investor Contact:",
"Corporate Presentation"
11/12/2021 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Investor Contact:"
11/03/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Investor Contact:"
08/12/2021 8-K Quarterly results
07/30/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : July 28, 2021 89bio, Inc. Delaware 001-39122 36-4946844 142 Sansome Street, Second Floor San Francisco, CA 94104 500-4614 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under..."
06/10/2021 8-K Quarterly results
06/04/2021 8-K Quarterly results
06/04/2021 8-K Quarterly results
05/13/2021 8-K Quarterly results
03/24/2021 8-K Quarterly results
11/10/2020 8-K Quarterly results
Docs: "EXHIBIT INDEX",
"89bio Reports Third Quarter 2020 Financial Results and Provides Corporate Update"
10/05/2020 8-K Quarterly results
09/14/2020 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Docs: "89bio Announces Positive Topline Results from its Phase 1b/2a Trial of BIO89-100 in NASH",
"Slide Presentation"
06/26/2020 8-K Submission of Matters to a Vote of Security Holders
06/04/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "EXHIBIT INDEX",
"89bio Appoints Veteran Finance Executive Lota Zoth to Board of Directors SAN FRANCISCO, June 4, 2020 — 89bio, Inc. , a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the appointment of Lota S. Zoth, CPA to its Board of Directors and as Chair of the Audit Committee. A veteran of the biopharmaceutical industry, Ms. Zoth brings more than 35 years of financial and strategic experience to her role. “We are very pleased to have someone of Lota's caliber join 89bio's Board of Directors,” said Rohan Palekar, CEO of 89bio. “Lota brings decades of financial, operational and board experience to 89bio, which we expect will prove valuable as we advance the clinica..."
05/13/2020 8-K Quarterly results
Docs: "EXHIBIT INDEX",
"89bio Reports First Quarter 2020 Financial Results and Provides Corporate Update"
05/04/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "EXHIBIT INDEX",
"Executive Employment Offer Letter, by and between 89bio, Inc. and Rohan Palekar",
"Executive Employment Offer Letter, by and between 89bio, Inc. and Ryan Martins",
"Executive Employment Offer Letter, by and between 89bio, Inc. and Hank Mansbach",
"Executive Employment Offer Letter, by and between 89bio, Inc. and Quoc Le-Nguyen"
04/23/2020 8-K Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
Docs: "EXHIBIT INDEX",
"Letter from Deloitte & Touche LLP"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy